Skip to content

Lead Program — OP01 — NextGen

A different approachto a difficult disease.

OP01 — NextGen Botulinum Neurotoxin is Object Pharma's lead investigational program, exploring a differentiated approach to Major Depressive Disorder. It is in preclinical development and has not been approved by any regulatory authority.

The unmet need

~322M

people estimated to be living with depression globally in 2023

$12T

projected cumulative global macroeconomic burden, 2025–2050

~0.46%

estimated annual share of global GDP

Source: Cao Z. et al., Nature Medicine, 2026 — global burden research; not OP01 evidence.

Scientific rationale

A non-systemic approach

OP01 is being investigated as a locally administered intervention — a different starting point from systemic psychiatric medicines.

A different biological hypothesis

OP01 development is guided by the hypothesis that facial neuromuscular modulation may influence emotional processing.

Complementary potential

Object Pharma is investigating whether a neurotoxin-based intervention could eventually complement existing therapeutic approaches.

The facial feedback hypothesis

Published research involving other botulinum neurotoxin products has explored whether modulating facial musculature can influence emotional processing — a scientific hypothesis Object Pharma is testing rigorously, beginning with Major Depressive Disorder.

External studies evaluated other botulinum neurotoxin products and do not constitute clinical evidence for OP01. OP01 is investigational and in preclinical development.

Next milestones

Early stage clinical trial (2028)

References
  • Cao Z. et al. Global economic burden of depression in 154 countries from 2025 to 2050. Nature Medicine, 2026.
  • Finzi E, Wasserman E. Treatment of depression with botulinum toxin A: a case series. Dermatol Surg, 2006.
  • Wollmer MA et al. Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr Res, 2012.
  • Finzi E, Rosenthal NE. Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res, 2014.
  • Magid M et al. Treating depression with botulinum toxin: a pooled analysis of randomized controlled trials. Pharmacopsychiatry, 2015.
  • Additional references pending editorial review.